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Peptidomimetic inhibitors targeting the CCR5-binding site on the
human immunodeficiency virus Type-1 gp120 glycoprotein
complexed to CD4
Abstract
A helical tyrosine-sulfated epitope in CCR5 that is recognized by the human immunodeficiency virus
type-1 envelope glycoprotein gp120 in its CD4-induced conformation can be mimicked structurally by a
cyclic ß-hairpin peptide containing two sulfated tyrosine residues at positons i and i+2 along one
ß-strand.
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A helical epitope in CCR5 that is recognized by the human 
immunodeficiency virus type-1 envelope glycoprotein gp120 in its 
CD4-induced conformation can be mimicked structurally by a 10 
cyclic ß-hairpin peptide containing two sulfated tyrosine residues 
at positons i and i+2 along one ß-strand. 
The entry of human immunodeficiency virus type-1 (HIV-1) 
into cells requires an association of the viral envelope 
glycoprotein gp120 first with the cellular receptor CD4 and 15 
then with one of the co-receptors, most commonly CCR5. 
Major conformational changes occur in gp120 after docking to 
CD41, commonly referred to as the CD4-induced (CD4i) state, 
which lead to the assembly of a highly conserved binding 
pocket for the N-terminus of CCR5. The high affinity 20 
interaction of the N-terminus of CCR5 with the gp120-CD4 
complex requires the unusual post-translational O-sulfation of 
several tyrosine residues, in particular, at positions 10 and 14 
in CCR5.2, 3 Interestingly, several human antibodies directed 
against this site in gp120, including the monoclonal antibody 25 
(mAb) 412d, are also tyrosine-sulfated (Tys) in their antigen 
binding sites.4 
 Recent NMR and crystallographic studies of structures 
formed by complexation of mAb 412d, or a CCR5-derived 
peptide, with gp120 and CD4,5 revealed that the tyrosine-30 
sulfated N-terminal segment of CCR5 interacts with the 
gp120-CD4 complex in a helical conformation (Figure 1A). 
The side chains of Tys10 and Tys14 in the CCR5-derived 
peptide align on one face of the helix and in the complex are 
sequestered in the CCR5 binding site. Most known inhibitors 35 
of the CCR5-gp120 interaction so far target the receptor 
CCR5. The structural studies described above, however, open 
new opportunities for the design of inhibitors that target the 
binding site for CCR5 on gp120. So far the only molecules 
that interact with the coreceptor binding site in the CD4i state 40 
are linear CCR5-derived peptides, the mAbs 48d and 17b, and 
nucleic acid ligands (aptamers).6-9 
 The design of cyclic peptidomimetics constrained into a ß-
hairpin conformation represent one possible approach to 
mimic α-helical epitopes,10-12 In this case, molecular models 45 
suggested that mimetic 1 containing an 8 residue hairpin loop 
mounted on a hairpin-stabilizing D-Pro-L-Pro template, and 
containing Tys residues at position-1 and -3, should provide 
an interesting structural mimic of the helical CCR5 epitope 
(Figure 1B/D). 50 
 
 
Fig. 1. A, the CCR5 peptide (res. 7-15 in orange, Tys10 and Tys14 are 
shown) docked with gp1205; B, mimetic 1; C, solution NMR structures of 
1; D, superimposition of one NMR structure of 1 (green/blue) and the 55 
CCR5-derived peptide (purple, sulfo groups yellow/orange) (PDB file 
2RLL). 
 
 To test this hypothesis, the target mimetic 1 was 
synthesized and its structure in aqueous solution was 60 
investigated by 1H-NMR spectroscopy. The NMR data 
provide strong support for a stable ß-hairpin backbone 
conformation in this cyclic peptide in aqueous solution. The 
appearance of a network of cross-strand NOEs, 3J(Hα,NH) 
coupling constants of >8 Hz for residues in the ß-strands, and 65 
slow NH exchange rates for peptide NH groups predicted to 
form cross-strand H-bonds, are all consistent with a stable ß-
hairpin conformation. Average solution structures calculated 
using NOE-derived distance restraints adopt a well-defined ß-
hairpin structure (Figure 1C) with a type-II' ß-turn formed by 70 
D-Pro-L-Pro, and a type-II turn formed by Gly4-Thr5. A 
superimposition of one typical NMR structure of 1 with the 
NMR structure5 of the CCR5-derived peptide (PDB file 
2RLL) is shown in Figure 1D. 
 The inhibitory activity of mimetic 1 was tested using a 75 
surface plasmon resonance biosensor (BIAcore) and the mAb 
17b, whose epitope directly overlaps the CCR5 binding site 
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on CD4i gp1205, 13-15. In a first step, mAb 17b was coupled to 
a CM5 sensor chip surface, and its binding affinity to a 
gp120-CD4 complex was measured using recombinant gp120 
from strain JR-FL pre-mixed with a five-fold excess of a 
tetrameric CD4 fusion protein (CD4-IgG2).16 The dissociation 5 
constant measured in this way (Kd=2.5 nM) was in good 
agreement with data published previously.17 Neither gp120 
nor CD4-IgG2 alone showed significant affinity for the 
immobilized 17b mAb in this assay. Next, fixed 
concentrations of gp120 from strain JR-FL (50 nM) and CD4-10 
IgG2 (250 nM) were preincubated with varying concentrations 
of mimetic 1, before elution over the immobilized 17b mAb. 
The dependence of the BIAcore response on mimetic 1 
concentration showed a sigmoid inhibition curve with an IC50 
of 25 µM (Figure 2). An analogue of mimetic 1 with both Tys 15 
residues replaced by Tyr (peptide 2) showed only weak 
inhibitory activity (IC50 ≈ 400 µM), confirming the expected 
importance of the sulfo groups for binding to CD4i gp120.2 
BIAcore was also used to show that gp120 interacts with 
CD4-IgG2, and that this interaction is not inhibited by 20 
mimetic 1. These results show that mimetic 1 inhibits the 
interaction between CD4i gp120 and the mAb 17b, by 
blocking the CCR5 binding site. 
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Fig. 2.  Top, sensorgrams from BIAcore competition inhibition assays, 45 
showing the decrease in response upon addition of increasing amounts of 
peptide 1 (0, 0.1, 1, 5, 10, 50, 100, 500 and 1000 µM) to fixed 
concentrations of gp120 from strain JR-FL (50 nM) and CD4-IgG2 (250 
nM) before elution over the mAb 17b immobilized on a CM5 sensor chip. 
Bottom, normalised response versus peptide concentration. 50 
 
 Next, we examined whether the mimetic can inhibit HIV-1 
infection. For this, two Env-pseudotyped viruses with high 
(NAB09pre.106)18 and comparatively low (JR-FL) sensitivity 
to the CCR5 inhibitors AD101 and PSC-RANTES were 55 
probed for their sensitivity to entry inhibition by mimetic 1 in 
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Fig. 3. Top, inhibitory potency of mimetic 1 for HIV-1 env-pseudotyped 
JR-FL (red) and NAB09pre.106 (blue). In green, HIV-1 unspecific 
antiviral activity tested with envelope of murine leukemia virus (MuLV). 
Pooled data of two assays are depicted. Bottom, Inhibitory activity (IC50) 70 
of mimetic 1 after preincubation with different concentrations of sCD4. 
Depicted are the 95% confidence intervals. 
a single-round infection assay using the luciferase reporter 
cells JC53-BL (TZM-bl).19, 20 Interestingly, mimetic 1 
exhibited inhibitory activity against the NAB9pre.106 strain. 75 
However, the inhibitory activity was of moderate potency, 
despite the relatively high sensitivity of this strain to other 
CCR5 inhibitors. The more resistant strain JR-FL was not 
inhibited by mimetic 1 in the concentration range tested 
(Figure 3, top). To test if addition of sCD4 might increase the 80 
inhibitory capacity of mimetic 1, JR-FL and NAB09pre.106 
were pretreated with different concentrations of sCD4 
(corresponding to the IC30 and IC50 of sCD4 for the respective 
virus). Interestingly, under these conditions, infection by JR-
FL was inhibited by mimetic 1 with a potency similar to that 85 
seen with NAB09pre.106. In contrast, the sensitivity of 
NAB09pre.106 for mimetic 1 was not affected by triggering 
the CD4i state, suggesting that in the context of the envelope 
of NAB09pre.106, the CCR5 binding site is exposed even 
before CD4 engagement, whereas the CCR5 binding domain 90 
within the JR-FL envelopes depends on CD4 induction. To 
show that the viral inhibition observed for mimetic 1 was not 
due to general cell toxicity, a control experiment was 
performed using murine leukemia virus. The results (not 
shown) demonstrated that this virus entered the cell 95 
independently of CD4, and so rule out toxic effects on the 
cells by 1. 
 The inhibitory activity observed here supports the initial 
design concept for mimetic 1 and its mode of action as an 
antagonist of the CCR5 binding site on CD4i gp120. 100 
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  3 
Transferring the CCR5 epitope from a linear to a cyclic 
conformationally constrained peptide opens new possibilities 
for structure-activity studies and optimization of affinity and 
specificity of the inhibitor using parallel synthesis and 
screening approaches 21. 5 
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